Human Immunodeficiency Viruses (HIV) Clinical Trials Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026

Name: Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Phase (Phase I, Phase II, Phase III, Phase IV, Preclinical), By Drug Type (Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Patient Population (Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations), By End User (Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

• Human Immunodeficiency Viruses (HIV) Clinical Trials market size has reached to $1.94 billion in 2025

• Expected to grow to $2.97 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%

• Growth Driver: Rising HIV Infections Driving Growth In HIV Clinical Trials Market Due To Increasing Disease Burden And Need For Effective Treatments

• Market Trend: Long-Acting Injectable Solutions In HIV Prevention Boosting Market

• North America was the largest region in 2025.

What Is Covered Under Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

Human immunodeficiency virus (HIV) clinical trials refer to research studies conducted on humans to evaluate the safety, efficacy, and potential outcomes of new drugs, therapies, vaccines, or treatment strategies aimed at preventing, managing, or curing HIV infection. These trials follow structured phases, from early safety testing to large-scale effectiveness studies, and help generate clinical evidence needed for regulatory approval and improved patient care.

The main phases of human immunodeficiency virus (HIV) clinical trials are phase I, phase II, phase III, phase IV, and preclinical. Phase I represents the initial stage of testing, conducted on a small group of healthy volunteers or patients. These trials assess drug types such as antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), long-acting injectable antiretrovirals, and experimental drugs, using study designs that include interventional studies, observational studies, and expanded access studies. Patient populations targeted in these trials include adults, pediatric patients, seniors, pregnant women, and high-risk populations, and the results are utilized by end users, including pharmaceutical companies, research institutes, hospitals, and others.

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Global Report 2026 Market Report bar graph

What Is The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size and Share 2026?

The human immunodeficiency viruses (hiv) clinical trials market size has grown strongly in recent years. It will grow from $1.94 billion in 2025 to $2.11 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to high global hiv disease burden, expansion of antiretroviral drug research, increased public and private funding for hiv studies, growth of clinical research infrastructure, regulatory support for hiv drug development.

What Is The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Growth Forecast?

The human immunodeficiency viruses (hiv) clinical trials market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing development of curative and preventive hiv therapies, rising adoption of adaptive trial designs, expansion of vaccine-focused hiv trials, growing use of ai in clinical research, increased focus on long-term safety and efficacy outcomes. Major trends in the forecast period include increasing adoption of decentralized clinical trial models, rising use of digital patient recruitment tools, growing focus on long-acting hiv therapies in trials, expansion of real-world evidence integration, enhanced use of data analytics in trial management.

Book your 30 minutes free consultation with our research experts

Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Segmentation

1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical

2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations

5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies

2) By Phase II: Dose-Finding Studies, Efficacy Studies

3) By Phase III: Pivotal Trials, Comparative Efficacy Studies

4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies

5) By Preclinical: In Vitro Studies, Animal Studies

What Is The Driver Of The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

The increasing incidence of human immunodeficiency virus (HIV) infections is expected to propel the growth of the human immunodeficiency virus (HIV) clinical trials market going forward. Human immunodeficiency virus (HIV) infections refer to the condition caused by the HIV virus attacking and weakening the immune system, increasing susceptibility to infections and potentially leading to AIDS. The increase in HIV infections is largely due to lack of awareness about transmission, resulting to risky behaviors and delayed testing that facilitate the virus’s spread. Human immunodeficiency virus (HIV) clinical trials help patients suffering from HIV infections by testing new drugs, vaccines, and treatment strategies to improve prevention, manage the virus more effectively, and ultimately reduce disease progression and transmission. For instance, in August 2024, according to the Minority HIV/AIDS Fund (MHAF), a US-based government agency, an estimated 39.9 million individuals worldwide were living with HIV in 2023, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the increasing incidence of human immunodeficiency virus (HIV) infections is driving the growth of the human immunodeficiency virus (HIV) clinical trials market.

Key Players In The Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market

Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio

Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Trends and Insights

Major companies operating in the human immunodeficiency virus (HIV) clinical trials market are focusing on developing innovative solutions such as HIV prevention injections to enhance treatment efficacy and reduce transmission rates. An HIV prevention injection refers to a long-acting injectable medication administered periodically to prevent HIV infection in high-risk individuals by blocking the virus from establishing infection in the body. For instance, in August 2025, Gilead Sciences Inc., a US-based pharmaceutical company, received an approval from the European Union for Yeytuo (lenacapavir) to treat HIV. It is a twice-yearly injectable HIV prevention treatment that offers high efficacy, nearly 100% in clinical trials, significantly reducing the risk of sexually acquired HIV-1 infection. Its long-acting dosing improves adherence and convenience compared to daily oral PrEP, addressing a major gap in HIV prevention. This is designed for adults and adolescents at increased risk, that aims to expand access and help reduce new HIV infections globally as part of comprehensive prevention strategies.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

In July 2025, Elliott Investment Management L.P., a US-based investment company; Patient Square Capital LP, a US-based health investment company; and Veritas Capital Fund Management L.L.C., a US-based investment company, acquired Syneos Health for $7.1 billion. With this acquisition, investment groups aim to accelerate Syneos Health's growth, enhance customer delivery, and transform the company into a tech-enabled leader in biopharma solutions. Syneos Health is a US-based pharmaceutical commercial company that offers human immunodeficiency virus (HIV) clinical trials.

Regional Outlook

North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

The human immunodeficiency virus (HIV) clinical trials market includes revenues earned by entities by providing services such as clinical study design and protocol development, patient recruitment and screening, and medical monitoring and care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026?

The human immunodeficiency viruses (hiv) clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency viruses (hiv) clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$2.11 billion
Revenue Forecast In 2035	$2.97 billion
Growth Rate	CAGR of 9.2% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Phase, Drug Type, Study Design, Patient Population, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Adoption Of Decentralized Clinical Trial Models

4.2.2 Rising Use Of Digital Patient Recruitment Tools

4.2.3 Growing Focus On Long-Acting Hiv Therapies In Trials

4.2.4 Expansion Of Real-World Evidence Integration

4.2.5 Enhanced Use Of Data Analytics In Trial Management

5. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Analysis Of End Use Industries

5.1 Pharmaceutical Companies

5.2 Research Institutes

5.3 Hospitals

5.4 Clinical Research Organizations

5.5 Academic Medical Centers

6. Human Immunodeficiency Viruses (HIV) Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size, Comparisons And Growth Rate Analysis

7.3. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Segmentation

9.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Phase I, Phase II, Phase III, Phase IV, Preclinical

9.2. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs

9.3. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Interventional Studies, Observational Studies, Expanded Access Studies

9.4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations

9.5. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users

9.6. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

First-In-Human Studies, Safety And Tolerability Studies

9.7. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Dose-Finding Studies, Efficacy Studies

9.8. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pivotal Trials, Comparative Efficacy Studies

9.9. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Post-Marketing Surveillance, Long-Term Safety Studies

9.10. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Preclinical, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

In Vitro Studies, Animal Studies

10. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Regional And Country Analysis

10.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market

11.1. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market

12.1. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market

13.1. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market

14.1. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

14.2. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market

15.1. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market

16.1. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market

17.1. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

17.2. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Human Immunodeficiency Viruses (HIV) Clinical Trials Market

18.1. Taiwan Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

18.2. Taiwan Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Human Immunodeficiency Viruses (HIV) Clinical Trials Market

19.1. South East Asia Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

19.2. South East Asia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market

20.1. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

20.2. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market

21.1. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market

22.1. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market

23.1. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market

24.1. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market

25.1. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market

26.1. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

26.2. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market

27.1. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market

28.1. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

28.2. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market

29.1. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

29.2. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market

30.1. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

30.2. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market

31.1. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

31.2. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market

32.1. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market

33.1. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

33.2. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market

34.1. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview

34.2. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Segmentation By Drug Type, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Regulatory and Investment Landscape

36. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Landscape And Company Profiles

36.1. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Human Immunodeficiency Viruses (HIV) Clinical Trials Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Company Profiles

36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Other Major And Innovative Companies

Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio

38. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market

40. Human Immunodeficiency Viruses (HIV) Clinical Trials Market High Potential Countries, Segments and Strategies

40.1 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2030 - Countries Offering Most New Opportunities

40.2 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2030 - Segments Offering Most New Opportunities

40.3 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Overview Of Key Products - Product Examples

Table 2: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Supply Chain Analysis

Table 4: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Raw Material Providers

Table 5: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Resource Providers

Table 6: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Manufacturers (Suppliers)

Table 7: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Distributors And Channel Partners

Table 8: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Key Technologies & Future Trends

Table 9: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Trends

Table 10: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major End Users

Table 11: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market - TAM, US$ Billion, 2025

Table 15: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Preclinical, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 99: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 100: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market - Company Scoring Matrix

Table 101: Johnson & Johnson Financial Performance

Table 102: F. Hoffmann-La Roche Ltd. Financial Performance

Table 103: Pfizer Inc. Financial Performance

Table 104: AbbVie Inc. Financial Performance

Table 105: Sanofi S.A. Financial Performance

Table 106: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Competitive Benchmarking (In USD Billions)

Table 107: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Competitive Dashboard

Table 108: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 109: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Phase, 2025 – 2030

Table 110: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030

Table 111: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Study Design, 2025 – 2030

List Of Figures

Figure 1: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Overview Of Key Products - Product Examples

Figure 2: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Supply Chain Analysis

Figure 4: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Raw Material Providers

Figure 5: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Resource Providers

Figure 6: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Manufacturers (Suppliers)

Figure 7: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Distributors And Channel Partners

Figure 8: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Key Technologies & Future Trends

Figure 9: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major Trends

Figure 10: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Major End Users

Figure 11: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market - TAM, US$ Billion, 2025

Figure 15: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Preclinical, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: Asia-Pacific, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: China, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: India, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Japan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Australia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Indonesia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South Korea, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Taiwan, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: South East Asia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Western Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: UK, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Germany, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: France, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Italy, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Spain, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Eastern Europe, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: Russia, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: North America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: USA, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Canada, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: South America, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Brazil, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Middle East, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Africa, Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 99: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 100: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market - Company Scoring Matrix

Figure 101: Johnson & Johnson Financial Performance

Figure 102: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 103: Pfizer Inc. Financial Performance

Figure 104: AbbVie Inc. Financial Performance

Figure 105: Sanofi S.A. Financial Performance

Figure 106: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Competitive Benchmarking (In USD Billions)

Figure 107: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Competitive Dashboard

Figure 108: Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 109: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Phase, 2025 – 2030

Figure 110: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030

Figure 111: Global, Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Gain ($ Billion), Segmentation By Study Design, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

HIV Drugs Market Report 2026 - Global Outlook – By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhi...

Antiviral Combination Therapy Market Report 2026 - Global Outlook – By Type (Branded, Generic), By Drug Combination (Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors, Integrase ...

Virtual Clinical Trials Market Report 2026 - Global Outlook – By Design (Observational Trials, Interventional Trials, Expanded Access Trials), By Phases (Phase II, Phase III, Phase IV), By Indication (CNS, Autoimmune Or ...

Viral Diagnostic Test Kits Market Report 2026 - Global Outlook – By Testing Approach (Traditional Tests, Rapid Test), By Test Type (Direct Fluorescent Antibody (DFA) Test, Immunochromatographic Assay, Reverse Transcripta...

Antivirals Market Report 2026 - Global Outlook – By Type (Branded, Generic), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes),...

Infectious Disease Therapeutics Market Report 2026 - Global Outlook – By Type (Drugs, Vaccines), By Disease (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases), By End-User (Hospitals And Clinics, Retail Pharm...

Clinical Trial Supplies Market Report 2026 - Global Outlook – By Services (Logistics And Distribution, Storage And Retention, Supply Chain Management, Packaging, Labeling, And Blinding, Comparator Sourcing), By Clinical ...

Frequently Asked Questions

How big is the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

The Human Immunodeficiency Viruses (HIV) Clinical Trials market was valued at $1.94 billion in 2025, increased to $2.11 billion in 2026, and is projected to reach $2.97 billion by 2030.

What is the Human Immunodeficiency Viruses (HIV) Clinical Trials market growth?

The global Human Immunodeficiency Viruses (HIV) Clinical Trials market is expected to grow at a CAGR of 8.9% from 2026 to 2035 to reach $2.97 billion by 2035.

Who are the key players in Human Immunodeficiency Viruses (HIV) Clinical Trials market?

Some Key Players in the Human Immunodeficiency Viruses (HIV) Clinical Trials market Include, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio .

What is the anticipated growth trend for the Human Immunodeficiency Viruses (HIV) Clinical Trials market?

Major trend in this market includes: Long-Acting Injectable Solutions In HIV Prevention Boosting Market. For further insights on this market. request a sample here

Which region has the most growth potential in the Human Immunodeficiency Viruses (HIV) Clinical Trials market?

North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.